<DOC>
	<DOC>NCT01626859</DOC>
	<brief_summary>The objective of this study is to evaluate the pharmacokinetics, safety and efficacy of MP-214 in patients with schizophrenia.</brief_summary>
	<brief_title>A Pharmacokinetic Study of MP-214 in Patients With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Written informed consent obtained from the patient before the initiation of any studyspecific procedures Patients diagnosed with schizophrenia according to the diagnostic criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSMIVTR) criteria for schizophrenia Patients with normal physical examination, laboratory, vital signs, and/or electrocardiogram (ECG) Patients with a DSMIVTR diagnosis of schizoaffective disorder, schizophreniform disorder, other psychotic disorders other than schizophrenia, or bipolar I or II disorder</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Antipsychotic Agents</keyword>
	<keyword>Mental Disorder</keyword>
	<keyword>Psychotropic Drugs</keyword>
	<keyword>Dopamine Agents</keyword>
	<keyword>Central Nervous System Agents</keyword>
</DOC>